IPA as a Causal Modulator of Epigenetic Aging via PXR‑Dependent Mitochondrial Reprogramming

Aaliya Owusu· Mar 21, 2026

Mechanism: Indole-3-propionic acid (IPA) activates PXR, enhancing mitochondrial function and SIRT1 activity, which modulates DNA methylation. Readout: Readout: This process is predicted to slow epigenetic aging clocks (GrimAge, DunedinPACE) and increase lifespan.

Hypothesis

We hypothesize that circulating indole-3-propionic acid (IPA) directly influences epigenetic aging rates by activating the pregnane X receptor (PXR) in peripheral tissues, leading to improved mitochondrial function and altered DNA methylation patterns that slow GrimAge and DunedinPACE.

Mechanistic Rationale

IPA crosses the blood-brain barrier and activates PXR, which suppresses Aβ accumulation and reduces microglial inflammation [https://www.science.org/doi/10.1126/sciadv.adw8410].
PXR activation is known to regulate mitochondrial biogenesis and oxidative phosphorylation in hepatocytes and cardiomyocytes [https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.648259/full].
Enhanced mitochondrial respiration reduces ROS production, a key driver of age‑related DNA methylation changes at CpG sites used in GrimAge and DunedinPACE.
In CKD models, IPA preserves macrophage autophagy and limits myocardial fibrosis, suggesting a broader role in tissue‑specific metabolic reprogramming [https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202501070].
Human intervention data show that Bifidobacterium supplementation raises IPA 1.91‑fold and improves neuronal function markers [https://pubmed.ncbi.nlm.nih.gov/37150125/], while polyphenol‑rich diets link IPA shifts to lower CRP [https://onlinelibrary.wiley.com/doi/full/10.1002/mnfr.202100349].
Despite these signals, no study has tied IPA levels to epigenetic clocks; we posit that IPA‑mediated PXR signaling modifies the activity of TET enzymes or DNMTs via altered NAD+/NADH ratios, thereby shifting methylation clocks.
Preliminary data indicate that PXR agonism increases SIRT1 activity, which deacetylates histones and promotes a more youthful epigenetic landscape.

Testable Predictions

In a longitudinal cohort of adults aged 45‑80, baseline serum IPA will inversely correlate with the rate of change in GrimAge and DunedinPACE over 3 years, independent of CRP, BMI, and kidney function.
Pharmacological activation of PXR with a selective agonist will recapitulate the IPA‑associated slowing of epigenetic clocks in IPA‑deficient germ‑free mice colonized with a tryptophan‑metabolizing bacterial strain.
Blocking PXR with antagonism will abolish the relationship between elevated IPA (via probiotic supplementation) and improved mitochondrial respiration measured in peripheral blood mononuclear cells.
Mendelian randomization using genetic variants influencing IPA synthesis (e.g., mutations in tryptophanase pathways) will show a causal effect on epigenetic age acceleration.
Individuals with high IPA will exhibit a lower mitochondrial ROS burst ex vivo and a higher NAD+/NADH ratio in circulating mononuclear cells.

Experimental Design

Recruit 600 participants from two community‑based cohorts; collect fasting serum IPA (UHPLC‑MS/MS, standardized protocol), GrimAge, DunedinPACE, and covariates at baseline and annually for 3 years.
Use mixed‑effects models to assess IPA as predictor of clock slope, adjusting for age, sex, smoking, medication, and baseline epigenetic age.
Conduct a power analysis assuming a moderate effect size (Cohen’s d = 0.4) to ensure 80 % power at α = 0.05.
In parallel, run a double‑blind RCT: 120 older adults receive either Bifidobacterium longum supplement or placebo for 6 months; measure IPA, mitochondrial respiration (Seahorse XF), NAD+/NADH ratio, and epigenetic clocks pre‑ and post‑intervention.
Include a mechanistic arm with IPA‑treated human hepatocytes and macrophages; assess PXR activation (reporter assay), TET2/DNMT1 activity, ROS production, and SIRT1 deacetylation.
Perform ex vivo mitochondrial stress tests on PBMCs to link IPA levels with spare respiratory capacity and proton leak.

If IPA predicts slower epigenetic aging and PXR blockade eliminates this effect, the hypothesis is supported; absent association or lack of PXR dependence would falsify it.

Mechanistic Rationale

IPA crosses the blood-brain barrier and activates PXR, which suppresses Aβ accumulation and reduces microglial inflammation [https://www.science.org/doi/10.1126/sciadv.adw8410].

PXR activation is known to regulate mitochondrial biogenesis and oxidative phosphorylation in hepatocytes and cardiomyocytes [https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.648259/full].

Enhanced mitochondrial respiration reduces ROS production, a key driver of age‑related DNA methylation changes at CpG sites used in GrimAge and DunedinPACE.

In CKD models, IPA preserves macrophage autophagy and limits myocardial fibrosis, suggesting a broader role in tissue‑specific metabolic reprogramming [https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202501070].

Human intervention data show that Bifidobacterium supplementation raises IPA 1.91‑fold and improves neuronal function markers [https://pubmed.ncbi.nlm.nih.gov/37150125/], while polyphenol‑rich diets link IPA shifts to lower CRP [https://onlinelibrary.wiley.com/doi/full/10.1002/mnfr.202100349].

Despite these signals, no study has tied IPA levels to epigenetic clocks; we posit that IPA‑mediated PXR signaling modifies the activity of TET enzymes or DNMTs via altered NAD+/NADH ratios, thereby shifting methylation clocks.

Preliminary data indicate that PXR agonism increases SIRT1 activity, which deacetylates histones and promotes a more youthful epigenetic landscape.

Testable Predictions

In a longitudinal cohort of adults aged 45‑80, baseline serum IPA will inversely correlate with the rate of change in GrimAge and DunedinPACE over 3 years, independent of CRP, BMI, and kidney function.

Pharmacological activation of PXR with a selective agonist will recapitulate the IPA‑associated slowing of epigenetic clocks in IPA‑deficient germ‑free mice colonized with a tryptophan‑metabolizing bacterial strain.

Blocking PXR with antagonism will abolish the relationship between elevated IPA (via probiotic supplementation) and improved mitochondrial respiration measured in peripheral blood mononuclear cells.

Mendelian randomization using genetic variants influencing IPA synthesis (e.g., mutations in tryptophanase pathways) will show a causal effect on epigenetic age acceleration.

Individuals with high IPA will exhibit a lower mitochondrial ROS burst ex vivo and a higher NAD+/NADH ratio in circulating mononuclear cells.

Experimental Design

Recruit 600 participants from two community‑based cohorts; collect fasting serum IPA (UHPLC‑MS/MS, standardized protocol), GrimAge, DunedinPACE, and covariates at baseline and annually for 3 years.

Use mixed‑effects models to assess IPA as predictor of clock slope, adjusting for age, sex, smoking, medication, and baseline epigenetic age.

Conduct a power analysis assuming a moderate effect size (Cohen’s d = 0.4) to ensure 80 % power at α = 0.05.

In parallel, run a double‑blind RCT: 120 older adults receive either Bifidobacterium longum supplement or placebo for 6 months; measure IPA, mitochondrial respiration (Seahorse XF), NAD+/NADH ratio, and epigenetic clocks pre‑ and post‑intervention.

Include a mechanistic arm with IPA‑treated human hepatocytes and macrophages; assess PXR activation (reporter assay), TET2/DNMT1 activity, ROS production, and SIRT1 deacetylation.

Perform ex vivo mitochondrial stress tests on PBMCs to link IPA levels with spare respiratory capacity and proton leak.

If IPA predicts slower epigenetic aging and PXR blockade eliminates this effect, the hypothesis is supported; absent association or lack of PXR dependence would falsify it.